Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 06 2022
Historique:
received: 09 03 2022
revised: 04 04 2022
accepted: 06 04 2022
pubmed: 19 4 2022
medline: 4 5 2022
entrez: 18 4 2022
Statut: ppublish

Résumé

Stapled peptides are promising scaffolds for inhibiting protein-protein interactions in cells, including between the intracellular oncoprotein MDM2 and p53. Herein, we have investigated the potential utility of a stapled peptide, VIP116, for developing radiolabeled agents targeting MDM2. VIP116 was radioiodinated using the prosthetic agent N-succinimidyl-3-[*I]iodobenzoate ([*I]SIB). The resulting labeled peptide [*I]SIB-VIP116 exhibited high uptake (165.3 ± 27.7%/mg protein) and specificity in SJSA-1 tumor cells. Tissue distribution studies of [*I]SIB-VIP116 revealed a peak tumor uptake of 2.19 ± 0.56 percent injected dose per gram (%ID/g) in SJSA-1 xenografts at 2 h post-injection, which was stable until 6 h. [*I]SIB-VIP116 exhibited high activity (8.33 ± 1.18%ID/g) in the blood pool but had high tumor-to-muscle ratios (12.0 ± 5.7), at 30 min. Metabolic stability studies in mice indicated that about 80% of the activity in plasma was intact [*I]SIB-VIP116 at 4 h. Our results confirm the cell permeability and specific binding of [*I]SIB-VIP116 to MDM2 and the suitability of the VIP116 scaffold for radiolabeled probe development.

Identifiants

pubmed: 35436588
pii: S0960-894X(22)00201-3
doi: 10.1016/j.bmcl.2022.128725
pmc: PMC9940446
mid: NIHMS1871000
pii:
doi:

Substances chimiques

Peptides 0
MDM2 protein, human EC 2.3.2.27
Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128725

Subventions

Organisme : NCI NIH HHS
ID : R21 CA241823
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Références

Clin Cancer Res. 2016 Feb 15;22(4):868-76
pubmed: 26459177
Molecules. 2019 Jun 20;24(12):
pubmed: 31226791
J Am Chem Soc. 2007 Mar 7;129(9):2456-7
pubmed: 17284038
Molecules. 2019 Oct 30;24(21):
pubmed: 31671554
Invest New Drugs. 2020 Jun;38(3):831-843
pubmed: 31359240
Chem Sci. 2020 May 11;11(21):5577-5591
pubmed: 32874502
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Mol Cancer Res. 2008 Feb;6(2):205-11
pubmed: 18314481
Oncogene. 1997 Aug 28;15(9):1001-10
pubmed: 9285554
Mol Pharm. 2021 Oct 4;18(10):3871-3881
pubmed: 34523337
Cell. 1997 Oct 31;91(3):325-34
pubmed: 9363941
J Am Chem Soc. 2019 Mar 13;141(10):4167-4181
pubmed: 30768253
J Med Chem. 2014 Aug 14;57(15):6275-88
pubmed: 24601557
J Nucl Med. 2022 Apr;63(4):536-542
pubmed: 34326125
Theranostics. 2018 Jan 1;8(3):735-745
pubmed: 29344302
Theranostics. 2016 Jan 01;6(1):78-92
pubmed: 26722375
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54
pubmed: 23946421
Nanomaterials (Basel). 2020 Apr 19;10(4):
pubmed: 32325827
Mol Imaging Biol. 2020 Aug;22(4):940-947
pubmed: 31907847
Sci Rep. 2017 May 11;7(1):1763
pubmed: 28496125
Clin Cancer Res. 2021 Oct 1;27(19):5236-5247
pubmed: 34301750
Pharmaceuticals (Basel). 2019 Jul 29;12(3):
pubmed: 31362406
ACS Chem Biol. 2013 Mar 15;8(3):506-12
pubmed: 23214419
EJNMMI Res. 2020 Apr 16;10(1):38
pubmed: 32300907
Nat Commun. 2019 Oct 14;10(1):4673
pubmed: 31611594
Mol Imaging Biol. 2018 Aug;20(4):501-509
pubmed: 29256046
J Am Chem Soc. 2005 Jul 27;127(29):10130-1
pubmed: 16028899
Pharmaceuticals (Basel). 2020 Mar 03;13(3):
pubmed: 32138377
Cancer Res. 2018 Sep 1;78(17):5084-5093
pubmed: 30026328
Expert Opin Drug Discov. 2010 Mar;5(3):235-48
pubmed: 22823020
Radiographics. 2015 Mar-Apr;35(2):500-16
pubmed: 25763733
Chem Sci. 2019 May 30;10(26):6457-6466
pubmed: 31316744
Anal Biochem. 2004 Sep 15;332(2):261-73
pubmed: 15325294
J Nucl Med. 2016 May;57(5):741-6
pubmed: 26769866
Nature. 1992 Jul 2;358(6381):80-3
pubmed: 1614537

Auteurs

Zhengyuan Zhou (Z)

Department of Radiology, Duke University Medical Center, Durham, NC 27710, United States.

Michael R Zalutsky (MR)

Department of Radiology, Duke University Medical Center, Durham, NC 27710, United States.

Satish K Chitneni (SK)

Department of Radiology, Duke University Medical Center, Durham, NC 27710, United States. Electronic address: satish.chitneni@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH